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Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, PennsylvaniaABSTRACT General anesthesia is a relatively safe medical procedure, which for nearly 170 years has allowed life saving
surgical interventions in animals and people. However, the molecular mechanism of general anesthesia continues to be a matter
of importance and debate. A favored hypothesis proposes that general anesthesia results from direct multisite interactions with
multiple and diverse ion channels in the brain. Neurotransmitter-gated ion channels and two-pore Kþ channels are key players in
the mechanism of anesthesia; however, new studies have also implicated voltage-gated ion channels. Recent biophysical and
structural studies of Naþ and Kþ channels strongly suggest that halogenated inhalational general anesthetics interact with gates
and pore regions of these ion channels to modulate function. Here, we review these studies and provide a perspective to
stimulate further advances.General anesthetics encompass a diverse array of com-
pounds seemingly having little in common besides hydro-
phobicity. Thus, the identification of common molecular
targets based on structure-activity relationships has been
challenging, especially for the inhalational anesthetics.
These volatile drugs are uncharged and small, lacking often
even the ability to form hydrogen bonds (1). From a molec-
ular recognition standpoint, these drugs are almost feature-
less and thus very promiscuous. Consequently, not all
binding events might elicit physiological effects. For
example, although it is clear that lipid bilayers bind inhala-
tional anesthetics, the search for relevant physiological con-
sequences of this interaction has proven difficult and
wanting (2,3). The realization that proteins also have hydro-
phobic recognition surfaces, typically cavities or pockets,
initially shifted the attention to soluble enzymes. Bacterial
and firefly luciferases are early examples of enzymes with
an easily measured function that was altered by roughly
appropriate concentrations of anesthetic compound (4–6).
However, modulation of the catalytic activity of nonneuro-
nal and, most importantly, nonmammalian proteins is not
sufficient evidence to deem these receptors clinically rele-
vant. Anesthetic targets ought to play a major role as regu-
lators of excitability in the central nervous system of
animals that exhibit typical reversible endpoints of anes-
thesia (e.g., unresponsiveness, immobility, etc.). Based on
this criterion, ion channels emerge as the most reasonable
candidates.Submitted June 1, 2015, and accepted for publication September 30, 2015.
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0006-3495/15/11/2003/9Remarkably, general anesthetics influence the activity of
many ion channels with widely divergent properties (2,7–
10). It is thus unlikely that only one class of ion channels
is responsible for all endpoints of anesthesia (unitary protein
hypothesis). Conversely, there is growing recognition that
multiple molecular pathways to anesthesia exist and that
different anesthetics can use one or more of these pathways
to produce an anesthetic state (10). Anesthetics have been
separated into groups based on these pathway preferences.
For example, propofol, etomidate, barbiturates, neuroste-
roids, and many inhalational anesthetics potently influence
the GABAA receptor and thus were termed GABAergic,
whereas ketamine, nitrous oxide, and xenon are more active
on NMDA receptors, and were termed glutamatergic (10).
These monikers are based almost entirely on electrophysio-
logical studies of various reductionist systems, and the
choices of ion channel were in part dictated by old evidence
suggesting that general anesthetics act on synaptic transmis-
sion rather than conduction (3,11). Definitive support for
this hypothesis remains elusive because in vivo studies using
either genetic or pharmacological manipulations of these
largely synaptic ligand-gated ion channels have been far
less convincing than the electrophysiology, particularly for
the inhalational anesthetics (12,13).
What are we missing? For one, a big family of ion chan-
nels has been largely ignored, as early studies suggested that
the voltage-gated ion channels are less sensitive than the
ligand-gated and background Kþ channels (2,3). In other
words, relatively high anesthetic concentrations modulate
these ion channels; with EC50 values somewhat higher
than those required for GABAAR modulation and in vivo
general anesthesia. However, voltage-gated ion channelshttp://dx.doi.org/10.1016/j.bpj.2015.09.032
2004 Covarrubias et al.are certainly relevant as they are found in the brain and other
excitable tissues, help set the membrane potential, deter-
mine initiation, propagation and repetitive firing of action
potentials, and govern vesicular transmitter release (8,14–
16). Also, the in vitro sensitivity criterion has been chal-
lenged on the grounds that it assumes a linear relationship
between channel activity, cellular activity, and ultimately or-
ganism function (17). Even the simplest of models lay this
notion to rest (10,17). Furthermore, recent studies have
demonstrated robust and selective effects of inhalational an-
esthetics on voltage-gated ion channels, identified putative
sites, and have gone further to demonstrate in vivo relevance
(8,9,18–24).
Focusing on mechanisms of action, this perspective sum-
marizes recent evidence supporting the emergence of the
voltage-gated Kv and Nav channel families to full status as
functionally relevantmolecular targets of general anesthetics.
Certainly, other voltage-gated ion channels are also emerging
as anesthetic target candidates (Cav and HCN channels)
(16,25–27); however, significant structural and functional as-
pects of these ion channels overlapwithNavandKv channels,
and thus our focus will not be entirely exclusionary.Electrophysiological and biophysical Insights
Modulation of Kv channels by halogenated inhalational
anesthetics
Pioneering studies of theDrosophila Shakermutant and het-
erologously expressed Kþ channels suggest that specific Kv
channels could be significant targets of inhalational general
anesthetics (28–33). In particular, Li and Correa demon-
strated that isoflurane potentiates the conductance of the
Drosophila ShakerB Kv channel by increasing the open
probability and the unitary conductance (29). Independently,
we showed that n-alcohols (with an apparent cut-off at
C6) and most general anesthetics, such as chloroform, halo-
thane, isoflurane, and propofol inhibit K-Shaw2, another
Drosophila Kv channel in the Shaker superfamily (20,34–
36). This inhibition is reversible, exhibits a saturable profile
over a range covering relevant concentrations, involves
amphiphilic interactions, and has fast on/off millisecond
kinetics (37,38). Despite their distinct chemical structures,
but consistent with their physicochemical properties and
the relatively nonspecific nature of the interactions,
n-butanol and halothane display overlapping sites in
the channel protein (38,39). Overall, the data suggest that
n-alcohols and halogenated inhalational anesthetics inhibit
K-Shaw2 by preferentially interacting with the channel’s
resting closed state and stabilizing it. In contrast, we later
discovered that sevoflurane uniquely potentiates the
K-Shaw2 conductance in a manner that is reminiscent of
the effect of isoflurane on the conductance of the ShakerB
Kv channel (20,28,29). This finding is particularly relevant
because sevoflurane is a relatively new inhalational anes-Biophysical Journal 109(10) 2003–2011thetic commonly used in the clinic (40). Sevoflurane-depen-
dent potentiation of K-Shaw2 exhibits high and low affinity
interactionswith apparent equilibrium dissociation constants
of the order of 60 mM and 4 mM, respectively (20). Positive
modulation of the K-Shaw2 conductance by sevoflurane
results from two major effects: shifting in the conduc-
tance-voltage (G-V) relation toward negative voltages, and
increasing the maximum conductance (Fig. 1, A andD) (20).
To explain these effects, kinetic modeling suggested that
sevoflurane increases the equilibrium constant of the chan-
nel’s opening step and inhibits a nonconducting state outside
the activation pathway (20) (Fig. 1 F). Additionally, sevo-
flurane similarly potentiates ShakerB, and the mammalian
homologs Kv1.2 (Fig. 1, C and E), Kv1.3, and Kv1.5
(9,20). The latter is particularly important because it sug-
gests that Kv1 channels might be relevant sevoflurane tar-
gets in mammalian excitable tissues. Currently, we do not
know why sevoflurane selectively potentiates some Kv
channels in contrast to the inhibitory action of other haloge-
nated inhalational anesthetics and propofol (20). Seemingly,
relatively subtle differences in anesthetic structure and Kv
channel structure/conformation determine the modulation.
For instance, isoflurane, a halogenated ether closely related
to sevoflurane, potentiates the activity of the ShakerB Kv
channel but inhibits the K-Shaw2 channel. In excitable tis-
sues, these differences might also be dictated by the diverse
heteromeric architecture of native Kv channel complexes,
which include accessory subunits (42,43).
Given the apparently unique ability of sevoflurane to
potentiate Kv channels, it is also not clear how such a modu-
lation could be associated with anesthesia. Considering that
there are many ways to achieve anesthesia endpoints, the
modulation of specific molecular targets is not as critical as
their placement within the neuronal circuitry. If anesthesia
depends on tilting the excitation-inhibition balance toward
inhibition, any manipulation that selectively dampens excit-
ability in these circuits might produce anesthesia. Sevoflur-
ane could achieve this by specifically potentiating Kv1
channels in critical neural circuits that oppose arousal. Alter-
natively, potentiation of Kv1 channels by sevoflurane might
be responsible for undesired anesthetic effects not directly
associated with hypnosis, such as dysphoria (44).Halogenated inhalational anesthetics target
electromechanical coupling and pore properties
in Kv channels
Based on the differential actions of n-alcohols onKv channels
and comparison of the amino acid sequences, we previously
hypothesized that general anesthetics target regions directly
involved in the electromechanical transduction mechanism
that governs voltage-dependent gating of Kv channels
(36,45,46). Supporting this hypothesis, we found that
swapping of the S4–S5 linker (13 amino acids) between K-
Shaw2 (anesthetic-sensitive) andKv3.4 (anesthetic-resistant)
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FIGURE 1 Positive allosteric modulation of Kv channels by sevoflurane. (A–C) Idealized G-V curves of Kv channels. (D and E) Idealized conductance
ratio (conductance in the presence of 1 mM sevoflurane over control conductance) – voltage relations. These curves are based on previously published exper-
imental data (20). The magnitude of the changes is better appreciated by examining the conductance ratio curves, which show significant sevoflurane-induced
increases in conductance over a physiologically critical range of membrane potentials for K-Shaw2 and Kv1.2, Kv1.2-G329T. (F) Kinetic scheme that ex-
plains the positive allosteric modulation of Kv channels by sevoflurane (20) (see text). [C], O, and I indicate distinct gating states: preopen closed, open, and
open nonconducting (possibly inactivated), respectively. The preopen closed might include an aggregate of resting/nonconducting states connected by
voltage-dependent transitions in the activation pathway. þA and –A represent binding and unbinding of the anesthetic.
Anesthetic Action on KV and NaV Channels 2005fully removes and confers inhibition by n-alcohols, respec-
tively (36,47). Moreover, there is a positive correlation
between the apparent anesthetic binding energy and the
a-helicity of the S4–S5 linker (37,47,48); and a single muta-
tion in the critical PVPVmotif of theK-Shaw2S6 tail (PVPA)
converts the inhibition by n-alcohols or halothane into poten-
tiation (39,49). This potentiation is greatly dependent on the
context provided by the S4–S5 linker both in K-Shaw2 and
other related chimeric Kv channels (47). Strengthening the
critical role of these interactions, gating perturbations
induced by n-butanol, and halothane yielded substantial
interaction energies between the S4–S5 linker residue
A326 and the S6-tail residues A417, Y419, and Y420
(2–>4 kcal/mol) (38). Therefore, regions critically respon-
sible for electromechanical transduction in Kv channels
(S4–S5 linker and the S6-tail) aremajor determinants of inha-
lational anesthetic action.
Recent studies continue to strengthen this conclusion. We
discovered that a single residue at a critical pivot point be-
tween the S4–S5 linker and the S5 segment determines the
specific potentiation of Kv1.2 and K-Shaw2 by sevoflurane
(G329 and T330 at equivalent positions in Kv1.2 and
K-Shaw2, respectively). Whereas G329T confers dramaticpotentiation of the Kv1.2 conductance by sevoflurane
(and other general anesthetics), T330G eliminates the robust
sevoflurane-induced potentiation of the K-Shaw2 conduc-
tance. However, the latter mutation does not affect the
sevoflurane-induced increase in maximum conductance
mentioned previously (Fig. 1, A and B). This indicates that
at least two separable mechanisms are involved in the posi-
tive modulation of the Kv channels by sevoflurane. One
mechanism might involve sites allosterically coupled to the
electromechanical transduction directly responsible for con-
trolling voltage-dependent gating (i.e., cavities in the vicinity
of contacts between the S4–S5 linker and the S6-tail). The
other mechanism might involve distinct sites, which could
modulate the channel’s pore region and thereby influence
the stability of the open state and/or the unitary conductance.A plausible mechanism of sevoflurane-dependent positive
modulation of Kv channels
Although sevoflurane similarly potentiates K-Shaw2 and
Kv1.2 channels (Fig. 1), there are quantitative differences.
The sevoflurane-induced changes are larger in K-Shaw2,
suggesting that differential efficacies might depend onBiophysical Journal 109(10) 2003–2011
2006 Covarrubias et al.intrinsic biophysical/structural properties of theKv channels.
Whereas the opening-reluctant K-Shaw2 exhibits relatively
high-voltage activation and unfavorable opening (zFV1/2 ¼
4 kcal/mol), the opening-permissive Kv1.2 exhibits rela-
tively low-voltage activation and more favorable opening
(zFV1/2 ¼ 5 kcal/mol). Therefore, there is a plausible
nonadditive inverse link between the energetics of the chan-
nel opening and sevoflurane action. Accordingly, a Kv1.2
mutation (G329T) that makes the channel opening-reluctant
(zFV1/2 ¼ 6 kcal/mol) greatly magnifies the sevoflurane-
induced positive modulation. A broader examination of the
modulation of a larger set of wild-type and mutant Kv chan-
nels from different subfamilies by sevoflurane revealed a
similar link (Q.L. and M.C., unpublished data). We propose
that the sevoflurane-induced positive modulation of Kv
channels is tightly linked to voltage-dependent gating. If
the channel’s native/mutant conformation exhibits an
unfavorable opening step (opening-reluctant), sevoflurane
binding to cavities involving regions that govern electrome-
chanical coupling would have significant leeway to promote
opening (i.e., a significant shift of the G-V relation toward
more negative voltages). By contrast, if the opening step is
already more favorable (opening-permissive), the leeway
for positive modulation by sevoflurane is limited and, there-
fore, the resulting shift of the G-V relation is smaller.
Supporting this relationship, K-Shaw2 A417V exhibits a
strongly leftward shifted G-V relation and lacks modulation
by sevoflurane (Fig. 1, A and D). There are, however, excep-
tions to this relationship; the G-V relation for K-Shaw2
T330G is not shifted and yet the ability of sevoflurane toFIGURE 2 Cartoon of a possible mechanism of sevoflurane action on a Kv cha
green, and blue rods represent voltage sensors, S4–S5 linker and pore-lining S6
binding sites. Light blue dots represent water molecules, and f(Vm) indicates
external (around selectivity filter) and internal sites (S4–S5 linker sites) stabilize
between the open/conducting and open/nonconducting conformations (note a p
Biophysical Journal 109(10) 2003–2011modulate this mutant is greatly diminished (Fig. 1, B and
D). Overall, these observations reveal that voltage-dependent
gating and positive modulation by sevoflurane are nonaddi-
tive (i.e., they are not independent), which strongly suggests
that the two processes interact. We suggest that the actions of
sevoflurane and voltage are not separable because voltage
sensing and sevoflurane binding act on the conformational
change that governs opening of the Kþ-selective pore
(Fig. 2).
The hypothesis discussed previously cannot explain the
voltage-independent effect of sevoflurane (i.e., the increase
in relative maximum conductance), which is resistant to
a mutation (K-Shaw2 T330G) that nearly abolishes the
voltage-dependent effect discussed previously. We propose
that the increase in maximum conductance might result
from increasing the unitary conductance and/or increasing
the maximum open probability by inhibiting a noncon-
ducting state outside the activation pathway. This inhibition
could stabilize the conducting conformation of the channel’s
selectivity filter (Fig. 2).Modulation of Nav channels by halogenated inhalational
anesthetics
Inhalational general anesthetics primarily inhibit Nav chan-
nels through modulation of inactivation gating (8,50–55).
Ouyang and Hemmings demonstrated that isoflurane inhibi-
tion ofNav 1.2, 1.4, and 1.5 results from a negative shift of the
steady-state inactivation curve associated with fast inactiva-
tion (52) (Fig. 3). Additionally, Nav1.2 showed significantnnel. For clarity, only two opposing pore-forming subunits are shown. Gray,
segments, respectively. Red brackets represent the selectivity filter and ion
a voltage-dependent equilibrium. Binding of sevoflurane (space-filled) to
s the open state by promoting opening and inhibiting the rapid equilibrium
ossible distortion of the selectivity filter in this conformation).
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FIGURE 3 Halogenated ethers generally induce a relative stabilization of the Nav channel inactivated state. (A–D) Idealized steady-state inactivation
curves for various Nav channels before and after exposure to the indicated concentrations of common halogenated inhalational anesthetics (ISO, isoflurane;
DES, desflurane; SEVO, sevoflurane). These curves are based on data independently published by various authors (19,50,52,54,56,57). The anesthetics
induce a negative shift in the steady-state inactivation curve, consistent with a relative stabilization of the inactivated conformation. The dashed vertical
line marks the typical resting membrane potential of mammalian neurons. Note a substantial shift in the available Naþ current at this membrane potential.
(E) Kinetic scheme that explains the major effects of halogenated inhalational anesthetics on Nav channels. The anesthetics bind with higher affinity to the
inactivated state and stabilize it (modulated receptor hypothesis).
Anesthetic Action on KV and NaV Channels 2007tonic block by isoflurane. Further work by Ouyang et al. re-
vealed that various halogenated anesthetics differed in their
ability to inhibit the Nav1.4 channel, possibly due to anes-
thetic-specific differences in the predominant mode of action
(56). For example, desflurane induced a large hyperpolariz-
ing shift of the steady-state inactivation curve, whereas halo-
thane and isoflurane exhibited use-dependent block, slowed
recovery from inactivation, and enhanced current decay.Mechanisms of the inhibition of a bacterial Nav channel by
halogenated inhalational anesthetics
Although multiple studies point to inactivation gating of
Nav channels as a key target of inhalational anesthetic mod-
ulation, the large size and pseudotetrameric architecture of
mammalian Nav channels has made it difficult to pinpoint
mechanistically relevant interactions. The discovery and
subsequent crystallization of bacterial Nav channels offered
an avenue for more detailed mechanistic exploration of
inhalational anesthetic action. Ouyang et al. demonstrated
that, like mammalian Nav channels, NaChBac is inhibited
by clinically relevant concentrations of isoflurane (0.2–
0.8 mM) (57). NaChBac shares similarity with eukaryotic
Nav and Cav channels (58). However, in contrast to theeukaryotic counterparts, NaChBac is tetrameric (resembling
Kv channels), which facilitates structure-function studies.
This might also affect anesthetic interactions. Nevertheless,
the inhibition of NaChBac by isoflurane involves electro-
physiological alterations similar to those observed in
mammalian Nav channels, namely a negative shift of the
steady-state inactivation curve and use-dependent block.
Ouyang et al. proposed that enhanced inactivation is the
primary mechanism of isoflurane-induced inhibition of
NaChBac (Fig. 3).
We independently assessed NaChBac modulation by sev-
oflurane, which displays some unexpected features (19). At
low and high concentrations (0.2 and 2 mM), sevoflurane
shifts both the G-V relation and steady-state inactivation
curve in the hyperpolarizing direction. Additionally, sevo-
flurane modestly accelerates recovery from inactivation
at both low and high concentrations. This acceleration is
opposite to the effect of other inhalational anesthetics on
both NaChBac and mammalian Nav channels, which exhibit
slowed recovery from inactivation consistent with stabiliza-
tion of an inactivated state. Gating modulation by sevoflur-
ane displayed no significant concentration dependence,
suggesting high-affinity interactions possibly saturated at
0.2 mM. However, 2 mM sevoflurane additionally inducesBiophysical Journal 109(10) 2003–2011
2008 Covarrubias et al.substantial acceleration of current decay, indicative of
enhanced inactivation and/or slow open-channel block.
Semiquantitative computational modeling based on a
strictly sequential six-state kinetic scheme previously pro-
posed for NaChBac (59) recapitulates sevoflurane modula-
tion by combining enhanced inactivation gating indirectly
resulting from more favorable voltage-dependent activation
(resembling Kv channels), and slow open-channel block
(19). The first and second assumptions are presumably asso-
ciated with sevoflurane’s high- and low-affinity interactions,
respectively.
Altogether, halogenated inhalational anesthetics act on
Nav channels to promote steady-state inactivation coupled
to voltage-dependent activation (Fig. 3). In most instances
this modulation is associated with slowed recovery from
inactivation indicating preferential binding to inactivated
Nav channels and stabilization of the inactivated state,
which also gives rise to use-dependent inhibition (an
apparent block resulting from cumulative inactivation). In
NaChBac, the unique but modestly accelerated recovery
from inactivation induced by sevoflurane appears to be
insufficient to counteract much more favorable steady-state
inactivation. Other common effects are consistent with
enhanced inactivation (accelerated current decay), but could
also result from slow open channel block. In the light of
these features, we could generally explain the action of
halogenated inhalational anesthetics by assuming classical
mechanisms of local anesthetic action (60). Combinations
of modulated and guarded receptor hypotheses could ac-
count for the state-dependent phenomenology depending
on the relatively specific interactions that may allow distinct
halogenated inhalational anesthetics to differentially induce
stabilization of the channel’s inactivated state (modulated
receptor) and open channel pore block (guarded receptor).
Whereas the first mechanism depends on preferential inter-
action with the channel’s inactivated state, the second in-
volves gated accessibility to an anesthetic pore-blocking
site (e.g., opening of an internal activation gate). The inter-
action with the inactivated state may not necessarily depend
on the opening of an internal activation gate. Given that
halogenated inhalational anesthetics share a general ability
to stabilize the inactivated state of bacterial and mammalian
Nav channels, a heuristic approach prompted us to adopt a
modulated receptor hypothesis as the dominant mechanism
of drug action (Fig. 3). By analogy to the Kv channel sce-
nario (above), we propose that inactivation gating and
gating perturbation by inhalational anesthetic binding in
Nav channels are nonadditive processes acting on the
same conformational change. The inactivation-independent
pore blocking mechanisms (tonic and use-dependent) are
not sufficiently defined, despite otherwise suggestive elec-
trophysiological features (52). At any rate, the complexity
of the phenomenology and the proposed interactions suggest
multiple modes of actions involving multiple sites on pro-
karyotic and eukaryotic Nav channels.Biophysical Journal 109(10) 2003–2011Structural and computational insights
Putative anesthetic sites in KV channels: K-Shaw2, Kv1.2
Based on the available x-ray crystal structures of activated/
open Kv1.2 channels in the lipid bilayer environment, we
have built experimentally consistent atomistic models of
the resting-closed conformation (61). To resolve site-specific
anesthetic affinities, molecular docking and molecular dy-
namics-based free energy calculations yielded distinct clas-
ses of putative binding sites in wild-type and mutant Kv
channels (Fig. 4). Kv1.2 harbors two sevoflurane sites within
the transmembrane domain of the channel at the internal
S4–S5 linker and the S5–S6 interface (pore domain) of adja-
cent subunits, and a third site flanking the selectivity filter
at the extracellular face of the channel. Similar putative bind-
ing sites were identified for halothane and sevoflurane
inK-Shaw2 andKv1.2-G329T (38). Essentially, themodeled
Kv1.2 sevoflurane binding sites can be grouped into two
subsets displaying relatively low and high affinities. The
low-affinity subset includes the S4–S5 linker and pore
domain sites, and the high-affinity subset includes pockets
around the selectivity filter. The S4–S5 linker site that is
closest to the key residue G329 displays ~sevenfold greater
affinity for the resting-closed conformation relative to the
activated-open conformation. These patterns are consistent
with the complexity of the functional effects previously dis-
cussed. In particular, the putative binding site subset impli-
cating the S4–S5 linker may help explain specific aspects
of the negative/positive modulation that is sensitive to muta-
tions affecting this region. Further work is necessary to un-
derstand how additional anesthetic binding sites might
contribute to functional modulation (e.g., the sevoflurane-
induced increase in maximum conductance).Putative anesthetic sites in Nav channels: NaChBac
Although structural information about eukaryotic Nav chan-
nels is scant, careful phylogenetic analyses together with
several independent x-ray crystallography studies have
made accessible an entire class of prokaryotic Naþ-selective
voltage-gated ion channels (62–64). Their significance as
proxies for the physiologically relevant mammalian coun-
terparts has been ascertained on the basis of functional
and structural studies (57–59,63,65). Molecular dynamics
flooding simulations on membrane-bound structural models
of NaChBac revealed putative binding of isoflurane and sev-
oflurane at four distinct locations (19,66) (Fig. 4). One site is
in the pore of the channel, suggesting that halogenated
ethers may hinder ion conduction. Surprisingly, this site is
accessible even when the pore and the aqueous compart-
ment at the intracellular side are disconnected. The fenestra-
tions present in the membrane-embedded region of the
channel seem to act as the long-hypothesized hydrophobic
drug access pathway (67). Adjacent to this binding site,
but somewhat distinct from it, is a second set of sites located
FIGURE 4 Putative sevoflurane sites. Lateral
views of Kv1.2 and NaChBac models in different
functional conformations. From in silico docking
of Kv1.2, three main binding sites are located at
the extracellular region next to the selectivity
filter (red), at the S5–S6 interface of adjacent sub-
units (brown), and at the S4–S5 linker (yellow).
NaChBac clustering analysis of flooding simula-
tions revealed four sites, extracellular site (red),
linker site (yellow), activation gate site (orange),
and cavity/fenestration site (green and purple).
Anesthetic Action on KV and NaV Channels 2009at the internal fenestration entrance; a third set of binding
sites is found at the interface between the S4–S5 linker
and the S6 helix bundle. In the open state, these sites are
formed by mostly hydrophobic side chains of S6 residues,
which create pockets with an ideal chemical character to
bind halogenated inhalational anesthetics. Finally, a fourth
set of binding sites is in a region surrounding the selectivity
filter at the interface between adjacent subunits (a pocket
created by residues belonging to the so-called pore-turret
and pore-helix). This is the only set of binding sites that is
directly accessible from the extracellular side. The potential
relevance of the binding sites surrounding the selectivity fil-
ter is supported by the observation of a marked state-depen-
dent affinity: binding is possible only in the most activated
states (Fig. 4). Conversely, binding at the fenestrations
occurs only in the closed deactivated states. Free energy cal-
culations confirmed the putative physiological relevance of
the sites by providing affinities in the submillimolar range.
The lack of systematic mutational studies, however, limits
the extent to which we can presently relate these putative
sites to functional effects of the anesthetics (e.g., stabiliza-
tion of the inactivated state versus pore block).Do Kv and Nav channels share molecular mechanisms of
sevoflurane action?
Sevoflurane is a relatively specific gating modulator that in-
duces opposite net effects on Kv and NaChBac channels
(Figs. 1 and 2), which have similar architectures and basic
gating mechanisms (58). This selectivity is surprising
because general anesthetics have been long regarded as
nonspecific agents. The conformational specificity probably
depends on relatively subtle structural differences in critical
gating regions. Consequently, in a state-dependent manner,
sevoflurane binding shifts the channel’s gating equilibrium
in a particular direction to stabilize/destabilize either closed,open, or inactivated conformations. At a fundamental level
sevoflurane probably interacts similarly with both Kv and
Nav channels (below). Supporting this idea, the binding pat-
terns for sevoflurane in Kv1.2, K-Shaw, and NaChBac are
remarkably similar (Fig. 4). Specifically, aside from the
NaChBac sites in the pore and fenestrations, all sites are de-
tected in regions lying at the level of the membrane interface,
suggesting that partially solvated protein pockets in these re-
gions and the dipolar field of the lipid bilayer provide a chem-
ical environment that matches the amphiphilic character of
halogenated ethers. The specific locations of the putative
binding sites in Kv and NaChBac channels are also relevant.
For instance, binding might occur at the subunit interface
behind the selectivity filter. In typical Kþ channels, this inter-
face helps regulate the stability of P/C-type inactivation (68).
Another interesting binding region involves the S4–S5 linker,
which plays a crucial role in the electromechanical mecha-
nism that governs voltage-dependent activation gating
(45,46). At this site, interactions with the anesthetic could
modulate the overall gating cycle. In contrast to the external
and internal sites common to Kv and NaChBac channels, the
cavity and fenestration sites are characteristic of NaChBac
and possibly other Nav channels. These sites might be signif-
icant specific determinants of the state-dependent mecha-
nism underlying anesthetic-induced stabilization of the
inactivated state that is typical ofNav channels.At critical ac-
cess locations, these sites might work independently or in
conjunction with sites involving the S4–S5 linker to modu-
late gating and pore blockade.Whether or not we can directly
extrapolate the information gained from studying NaChBac
to mammalian systems depends on learning more about the
three-dimensional structures of eukaryotic Nav channels at
the atomic level. Moreover, studies of mammalian Kv and
Nav channels at an organismal level would be necessary to
ultimately confirm the relevant roles of these ion channels
in general anesthesia.Biophysical Journal 109(10) 2003–2011
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The differential outcomes of the interactions between halo-
genated inhalational anesthetics and Kv and Nav channels
probably depend on how the voltage-dependent conforma-
tional energy landscape of a particular ion channel affects
anesthetic binding and vice versa. However, inferring the
nature and location of real anesthetic binding sites from
the modulatory behavior alone (top-down approach) is a
lengthy process that can be carried out only for a few ligand
chemotypes, channel-types, and conformations. Whether or
not we can transfer these inferences to a larger set of ligands,
ion channels, and conformations remains a challenge. Spe-
cial attention will have to be devoted to channel/drug inter-
actions in intermediate channel conformations as growing
evidence from both theoretical and experimental studies
points to the critical role of these hidden interactions. Crit-
ically, what is still missing is a bottom-up solution of the
problem. This approach implies demonstrating actual ligand
binding (from NMR studies and photolabeling) and predict-
ing from first principles how this interaction could ulti-
mately affect the conformational equilibriums of the ion
channel. This, however, is not a trivial problem as ligand
binding may be a necessary but not sufficient condition to
achieve a modulatory effect. Shedding light on this topic
will require an entire new series of high-resolution experi-
mental and computational studies aiming at describing
gating energetics of ion channels in the absence and
presence of site-specific bound ligands. New advances in
time-resolved x-ray/neutron interferometry and free-energy
molecular dynamics calculations might help achieve this
goal (19,66,69).AUTHOR CONTRIBUTIONS
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